TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04797364

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic Testing
Description: Participants will donate a 2ml (teaspoon) sample of saliva. DNA extracted from the saliva sample will be used for genotyping. Genotyping results will be translated into an interpretative clinical report using evidence-based software (Sequence2Script) developed by our group and delivered to the treating physician for use in their clinical decision-making. The report will contain genotyping results, predicted phenotype, and evidence-based drug selection and dosing recommendations relevant to the child's current and future care
Study: NCT05962658

Intervention type: OTHER
Intervention: qEEG
Description: qEEG data was collected with patients and healthy individuals in resting eyes-closed: the relative spectral power of the frequency bands delta, theta, alpha and beta was evaluated.

Intervention type: OTHER
Intervention: qEEG
Description: qEEG data was collected with patients and healthy individuals in resting eyes-closed: the relative spectral power of the frequency bands delta, theta, alpha and beta was evaluated.
Study: NCT06056076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mini Squats Training
Description: Mini Squats at a rate of ten squats at minimum range around 10-15 degrees at start along with Interferential Therapy for 10 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endurance Training
Description: Endurance training by the use of medium resistance therapeutic band at start along with Interferential Therapy for 10 minutes.
Study: NCT05842590

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Composite Veneer Restoration
Description: This is a single-arm study. Direct composite veneer Restorations will be performed to all patients.
Study: NCT06122038

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tart Cherry Extract Powder
Description: Tart Cherry Extract Powder (NordicCherry, SpecNova, LLC). Dispensed during visit 1. Participants will consume 1 dose per day for 10 days.
Study: NCT05228873

Intervention type: DRUG
Intervention: Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng)
Description: Patients take Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng), one bag of decoction (90ml) two times a day for 10 days. Ingredients per formula (tang): 12 grams of honey-fried Radix Glycyrrhizae, 6 grams of Rhizoma Zingiberis (stir-baked), 6 grams of Panax Ginseng. The decoction of concentrated extract is packed into aluminum foil vacuum bag, 90ml per bag, 1 formula (tang) is equivalent to 2 bags. Patients use the decoction directly from the bag.
Study: NCT04515602

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary debulking surgery
Description: Primary debulking surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary debulking surgery
Description: Primary debulking surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant chemotherapy
Description: 3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant chemotherapy
Description: 3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PARPi
Description: For patients with gBRCA/sBRCA mutation and CR/PR after first-line chemotherapy, maintenance therapy of PARP inhibitors.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PARPi
Description: For patients with gBRCA/sBRCA mutation and CR/PR after first-line chemotherapy, maintenance therapy of PARP inhibitors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PARPi
Description: For patients with gBRCA/sBRCA mutation and CR/PR after first-line chemotherapy, maintenance therapy of PARP inhibitors.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PARPi
Description: For patients with gBRCA/sBRCA mutation and CR/PR after first-line chemotherapy, maintenance therapy of PARP inhibitors.
Study: NCT06122038

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rice power placebo. Dispensed during visit 1. Participants will consume 1 dose per day for 10 days.
Study: NCT06496880

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oxyjun TM
Description: One capsule daily to be taken after breakfast for 56 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule daily to be taken after breakfast for 56 days
Study: NCT05505006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose Injection
Description: Anemic patients with ID will receive i.v. iron. Dosage will be based on Hb level and patient body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Anemic patients with folate deficiency will receive folic acid 5 mg per day for 1 month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B12
Description: Anemic patients with B12 deficiency will receive B vitamin complex 1 tablet per day for 1 month
Study: NCT05350852

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ThisCART19A
Description: ThisCART19A is a new type CAR-T cells therapy for patients with acute B-cell leukemia

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ThisCART19A
Description: ThisCART19A is a new type CAR-T cells therapy for patients with acute B-cell leukemia

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ThisCART19A
Description: ThisCART19A is a new type CAR-T cells therapy for patients with acute B-cell leukemia
Study: NCT06473792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic Toothpaste
Description: Composition: Main - Water, calcium carbonate, calcium glycerophosphate, glycerin, xylitol, sodium bicarbonate, sweet fennel oil (Foeniculum vulgare), carrageenan, maltodextrin, Dental-Lac (Lactobacillus paracasei), potassium sorbate, yucca (Y. filamentosa) powder, stevia leaf extract (Eupatorium rebaudiana bertoni), zinc chloride.~Usage: This is mint flavored toothpaste containing Lactobacillus paracasei which has demonstrated the ability to help address harmful strains of oral flora, and promotes the maintenance of a healthy teeth and gums. The participant will be instructed to brush with it twice daily.
Study: NCT04983355

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Hydrolysate
Description: The participants take 4 capsules/day of the study product. Two capsules should be consumed orally every morning with breakfast and/or with a glass of (plain, not sparkling) water and not with fruit juice or hot food/drink while ingesting the capsules; and two capsules should be consumed orally every evening with their dinner and/or with a glass of water.~Participants receiving the fish hydrolysate the fourth first weeks will then receive the placebo during another 4 weeks. A wash-out period of 4 weeks is included between each phase of supplementation.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants take 4 capsules/day of the study product. Two capsules should be consumed orally every morning with breakfast and/or with a glass of (plain, not sparkling) water and not with fruit juice or hot food/drink while ingesting the capsules; and two capsules should be consumed orally every evening with their dinner and/or with a glass of water.~Participants receiving the Placebo the fourth first weeks will then receive the fish hydrolysate during another 4 weeks. A wash-out period of 4 weeks is included between each phase of supplementation.
Study: NCT06096662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Verb Network Strenghtening Treatment (VNeST)
Description: Participants are presented with a verb (representing an activity, for example, to drive) orally and in writing. The participants are first asked to name someone who may perform a given activity (an agent/subject, for example a chauffeur), then to name an object which the named activity can pe performed with (a patient/object, for example a limousine). Several types of semantic cues and assistance are given if the participant has difficulties finding adequate nouns). This procedure is repeated for three different agents and objects related to the given verb. The participants is then asked to choose one of the three sentences participants have created and expand on it by telling where, when and why the agents are performing the activity. After this, the participants are given sentences (with several foils) including the activity as well as agents and objects/patients, and are asked to indicate whether the sentences are plausible or not.
Study: NCT06427616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short Duration Moderate Intensity Soleus Push-ups
Description: Participants will start soleus push-ups in sitting positions. To do so, the participants will be in a seated position, the legs will be at 90 degrees to the floor, feet will be placed flat on the ground. Participants will then move their heels up and down continuously.~Soleus push-ups will be performed with moderate intensity using weights which will be placed on their laps.~Participants will perform this activity till their 60-80% of their maximum heart rate is achieved and maintained

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sustained Soleus Push-ups
Description: Participants will start soleus push-ups in sitting. To do so, the participants will be in a seated position, the legs will be at 90 degrees to the floor, and feet will be placed flat on the ground. Participants will then move their heels up and down continuously for.~Sustained soleus push-ups will be performed with light intensity for up to 270 mins.~No external resistance will be added. Participants will be provided with a maximum of 4 min break time after every 90 mins intervention. In the meantime, their blood sample will be collected
Study: NCT06045468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amputation-specialized rehabilitation
Description: Study center; amputation-specialized unit within rehabilitation facility; fully practicing national guidelines

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-amputation-specialized rehabilitation
Description: Control clinics; treating some amputated patients each year but do not practice national guidelines or partially practicing national guidelines
Study: NCT05889429

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scans
Description: The MRI protocol will include standard anatomical, functional, and diffusion imaging, and spectroscopy sequences.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scans
Description: The MRI protocol will include standard anatomical, functional, and diffusion imaging, and spectroscopy sequences.

Intervention type: BEHAVIORAL
Intervention: clinical assessments
Description: Several clinical assessments will be performed to evaluate the recovery of motor functions. Initially and for screening, the cognitive ability will be assessed using the Montreal Cognitive Assessment (MoCA), and visuospatial neglect will be assessed using the Star Cancellation Test (SCT). eligible participants that meet all inclusion criteria will undergo a series of clinical function tests during each test session (t1-t4) to assess clinical outcomes.
Study: NCT05541575

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR films
Description: A new virtual reality course for home care workers to experience the view of dementia people with BPSD and the relative feelings.
Study: NCT05348200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monad 1
Description: Single therapy cream containing Lidocaine. Lidocaine is a topical anesthetic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monad 2
Description: Single therapy cream containing Halobetasol Propionate (low-strength). HPB is a topical corticosteroid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monad 3
Description: Single therapy cream containing Halobetasol Propionate (high strength).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination - CITI-002 (low dose)
Description: Combination cream containing Lidocaine and HBP (low)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination - CITI-002 (high dose)
Description: Combination cream containing Lidocaine and HBP (high)
Study: NCT06291558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The first 5 minutes of heating in the exercise program are planned to be implemented for 8 weeks, and the last 5 minutes are a cooling period. In the exercise program, which is planned to last 40 minutes in total, respiratory exercises will be applied to heating and cooling peryotes. As respiratory exercise, diaphragmatic respiratory exercise will be applied to heating and cooling peryots with 5 repetitions. Elastic resistant bands (Therand) will be used in resistant exercise training that will last for 30 minutes. The participants will be started to work with the resistance that they can do 10 again but cannot reach 14 repetitions. Elastic resistant bands are shoulder flexion, shoulder extension, shoulder ablution, shoulder horizontal abduction, elbow extension, hip ablution, hip flexion, and hip exercise. These exercises will be held once a week, 10 repetitions, 2 sets, for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The first 5 minutes of heating in the exercise program are planned to be implemented for 8 weeks, and the last 5 minutes are a cooling period. In the exercise program, which is planned to last 40 minutes in total, respiratory exercises will be applied to heating and cooling peryotes. As respiratory exercise, diaphragmatic respiratory exercise will be applied to heating and cooling peryots with 5 repetitions. Elastic resistant bands (Therand) will be used in resistant exercise training that will last for 30 minutes. The participants will be started to work with the resistance that they can do 10 again but cannot reach 14 repetitions. Elastic resistant bands are shoulder flexion, shoulder extension, shoulder ablution, shoulder horizontal abduction, elbow extension, hip ablution, hip flexion, and hip exercise. These exercises will be held once a week, 10 repetitions, 2 sets, for 8 weeks.
Study: NCT05886569

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIGIPREDICT Physiopatech
Description: Application of the DIGIPREDICT Physiopatch investigational device
Study: NCT06190561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07940367
Description: Participants to receive a single dose of PF-07940367 product II 150 mg by mouth
Study: NCT06020703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fermented Food Diet
Description: Subjects will incorporate 1 serving of fermented food a day and increase to 6 more each day as tolerated for 4 weeks. After the initial 4 weeks, subjects will eat 6 or more servings of fermented foods each day for 8 weeks.
Study: NCT06190561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07940367
Description: Participants to receive a single dose of PF-07940367 product I 150 mg by mouth
Study: NCT06207526

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blended face-to-face and smartphone intervention
Description: The intervention comprises two phases: an initial stage involves baseline assessment, in-depth app training, psychoeducation, and EMA monitoring for functional analysis. The subsequent phase focuses on identifying and implementing individual coping strategies, forming the basis for daily personalized EMI reminders. Over six days, participants receive ten daily surveys to gauge fluctuations in paranoia and delusional ideation. EMA-derived feedback, considering antecedents and coping responses, shapes a personalized EMI. Four sessions with a psychologist involve discussing app feedback, emphasizing functional analysis, coding coping strategies into the app, assessing utility, and adapting as needed. Post-session two, five coping reminders and an eight-item evening survey are sent daily for two blocks of ten days to monitor delusional ideations and coping strategy effectiveness.
Study: NCT06096415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX-101 1mg
Description: ABX-101 1mg will be provided to patients stratified 1:1 by GCS scoring (GCS 4-8; GCS 9-12)
Study: NCT05899738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Specified dose on specified days
Study: NCT06469723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INFA Program
Description: Participants will be screened using the INFA Screening tool, comprising of assessments for multiple domains that are part of existing routine admission nursing assessments, including functional decline, delirium, recurrent falls, self-reported hearing and visual impairment questionnaires, malnutrition risk, oral health, and dysphagia screening. Nurse-led protocols will be done to address each identified geriatric syndrome.~Participants with complex cases (defined as delirium and/or high-risk falls) will be referred to the GeriCARE service, with capabilities for performing comprehensive geriatric assessment (CGA) guiding discharge planning. Referrals to geriatricians can be initiated whenever necessary, facilitating access to specialised geriatric medical expertise.~Participants will also receive comprehensive discharge planning and systematic follow-up procedures, done by ward resource nurses.
Study: NCT05467501

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theraputic ultrasound
Description: Therapeutic ultrasound

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Theraputic ultrasound
Description: Therapeutic ultrasound
Study: NCT05489367

Intervention type: BIOLOGICAL
Intervention: sars cov 2 biontec vaccine
Description: volunteers will be expected to receive 2 doses of vaccine
Study: NCT05747703

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ria Treatment Platform
Description: combined medication, coaching, education, and monitoring
Study: NCT05373849

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: essentiel oil mixtures in inhaler sticks (step 1) - no intervention (step 2)
Description: The participant will receive the study treatment (essential oils mixture in inhaler sticks for 2 months) and the control (no intervention for 2 months). At inclusion and at the end of each period, questionnaires of well-being, anxiety and stress will be completed

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: essentiel oil mixtures in inhaler sticks (step 1) - no intervention (step 2)
Description: The participant will receive the study treatment (essential oils mixture in inhaler sticks for 2 months) and the control (no intervention for 2 months). At inclusion and at the end of each period, questionnaires of well-being, anxiety and stress will be completed

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: no intervention (step 1) - essential oils mixture in inhaler sticks (step 2)
Description: The participant will receive the control (no intervention for 2 months) and the study treatment (essential oils mixture in inhaler sticks for 2 months). At inclusion and at the end of each period, questionnaires of well-being, anxiety and stress will be completed.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: no intervention (step 1) - essential oils mixture in inhaler sticks (step 2)
Description: The participant will receive the control (no intervention for 2 months) and the study treatment (essential oils mixture in inhaler sticks for 2 months). At inclusion and at the end of each period, questionnaires of well-being, anxiety and stress will be completed.
Study: NCT06174610

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of Renal Resistive Index
Description: The kidneys are preliminarily visualized in a 2D projection, followed by identifying interlobar or arcuate vessels using color Doppler. Flow measurements in these vessels are performed using pulsed-wave Doppler. Renal Resistive Index is determined over three cardiac cycles (five in the case of atrial fibrillation) in two different arteries, each in a different kidney section. Subsequently, measurements from each artery are averaged. If possible, the examination should be conducted bilaterally.~The investigators do not have access to previous measurements (each study is recorded on a separate card).
Study: NCT05641415

Intervention type: OTHER
Intervention: Imaging
Description: MRI and x-ray of both shoulders
Study: NCT05888987

Intervention type: BIOLOGICAL
Intervention: PCR multiplex by FilmArray
Description: PCR multiplex by FilmArray system on corneal swabbing sample
Study: NCT05326867

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infiltration of 2% Lidocaine with Needle
Description: Infiltration of 2% Lidocaine with Needle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infiltration of 2% Lidocaine without Needle
Description: Free needle infiltration of lidocaine can be an alternative to reduce epidural needle insertion pain. The study of Gozdemir et al. found that 10% lidocaine infiltration without needle was less painful than 2% lidocaine infiltration with a 27G needle with no significant difference in analgesia effect during epidural needle insertion. This study aimed to compare infiltration of lidocaine with and without needle for epidural needle insertion
Study: NCT06576401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] HDM1002
Description: Administered orally